Genomic analysis of 733 HER2+breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities

被引：0
|
作者：
Ferraro, Emanuela
Smith, Alison
Safonov, Anton
De Lara, Paulino Tallon
Bernado, Cristina
Lahuerta, Enrique J. Arenas
Arribas, Joaquin
Solit, David
Reis-Filho, Jorge S.
Rosen, Neal
Norton, Larry
Modi, Shanu
Robson, Mark E.
Dang, Chau T.
Curigliano, Giuseppe
Chandarlapaty, Sarat
Razavi, Pedram
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS3-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS3-03
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Response to anti-HER2 neoadjuvant chemotherapy in invasive breast cancers with different HER2 FISH-positive patterns
    Lv, Hong
    Bai, Qian-Ming
    Liu, Yin
    Wang, Zhong-Hua
    Shui, Ruo-Hong
    Lu, Hong-Fen
    Xu, Xiao-Li
    Yu, Bao-Hua
    Tu, Xiao-Yu
    Bi, Rui
    Cheng, Yu-Fan
    Zhou, Xiao-Yan
    Shao, Zhi-Min
    Yang, Wen-Tao
    CANCER RESEARCH, 2022, 82 (04)
  • [42] Pathological evaluation of HER2 overexpression: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab)
    Umemura, S
    Sekido, Y
    Itoh, H
    Osamura, RY
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (02) : 77 - 81
  • [43] DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
    Menyhart, Otilia
    Budczies, Jan
    Munkacsy, Gyongyi
    Esteva, Francisco J.
    Szabo, Andras
    Puig Miquel, Teresa
    Gyorffy, Balazs
    ONCOTARGET, 2017, 8 (44) : 77207 - 77218
  • [44] DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer
    Gyorffy, B.
    Munkacsy, G.
    Esteva, F. J.
    Miquel, T. P.
    Menyhart, O.
    CANCER RESEARCH, 2016, 76
  • [45] THE IMPORTANCE OF HER2-ECD EXPRESSION CHECK FOR SELECTION OF ANTI-HER2 REGIMEN FOR BETTER OUTCOME OF HER2+ADVANCED AND RECURRENT BREAST CANCER
    Miwa, Noriko
    Ohnishi, Takahito
    Nakamura, Seigo
    BREAST, 2019, 48 : S53 - S54
  • [46] New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy
    Laing, L.
    Burns, D.
    MacNeil, I.
    Rich, B.
    Huang, Y.
    Myhre, S.
    Soltani, S.
    Sullivan, B.
    CANCER RESEARCH, 2017, 77
  • [47] Targeting HER2+breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
    Owen, Shawn C.
    Patel, Nish
    Logie, Jennifer
    Pan, Guohua
    Persson, Helena
    Moffat, Jason
    Sidhu, Sachdev S.
    Shoichet, Molly S.
    JOURNAL OF CONTROLLED RELEASE, 2013, 172 (02) : 395 - 404
  • [48] Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients
    Huszno, Joanna
    Nowara, Elzbieta
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (01): : 1 - 7
  • [49] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Hou, Yanjun
    Nitta, Hiroaki
    Wei, Lai
    Banks, Peter M.
    Portier, Bryce
    Parwani, Anil V.
    Li, Zaibo
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 447 - 457
  • [50] HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Yanjun Hou
    Hiroaki Nitta
    Lai Wei
    Peter M. Banks
    Bryce Portier
    Anil V. Parwani
    Zaibo Li
    Breast Cancer Research and Treatment, 2017, 166 : 447 - 457
12345